The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Organ infiltration in AML: treatment approaches and unmet needs
Monica Cusan, MD, Ludwig-Maximilians University, Munich, Germany, comments on the impact of organ infiltration on patient prognosis and treatment in acute myeloid leukemia (AML). Dr Cusan notes that organ infiltration is associated with a worse prognosis and requires specific treatment. She discusses the need for a better diagnostic tool to identify extramedullary manifestations, allowing for early detection and specialized treatment approaches. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the organ infiltration in AML is supposed to be between 2% to 8% of patients, although we know that it can also rise up to 22% of patients. And it is associated with a worse prognosis, and the patients get a particular treatment for the extramedullary manifestation. So usually the patients having, by chance, a node on the skin or a problem with the bowel, they get diagnosed with extramedullary manifestations of leukemia...
So the organ infiltration in AML is supposed to be between 2% to 8% of patients, although we know that it can also rise up to 22% of patients. And it is associated with a worse prognosis, and the patients get a particular treatment for the extramedullary manifestation. So usually the patients having, by chance, a node on the skin or a problem with the bowel, they get diagnosed with extramedullary manifestations of leukemia. Usually those patients can get operations or surgical resection of these nodes. Mostly patients get aggressive chemotherapy and they get radiation of the residual mass of the extramedullary manifestations and also they get planned for allogeneic transplantation. So what I suggest or what is my aim is to get a better diagnostic tool for these patients, ideally applying also like a CT scan or PET CT scan for these patients also where we don’t, let’s say think about extramedullary manifestation most probably they have one so I would like also to characterize more with ultrasound and other imaging tools to see if we have an extramedullary manifestation that we don’t see and so we will catch those patients that do not respond to classical standard therapy
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
